Pulse Biosciences Hits Enrollment Halfway Mark in Pivotal AFib Trial
PLSE has more than doubled off its 52-week low of $12.56 on elevated volume (1.9× avg).
Summary
Pulse Biosciences has enrolled more than half the patients in its U.S. pivotal trial for the nPulse Cardiac Catheter System, a key step toward FDA approval for treating atrial fibrillation.
Key Events · Product Development and Regulatory · PLSE
-
Enrollment Midpoint Reached
As of July 29, 2026, the NANOPULSE-AF IDE pivotal study has surpassed 50% enrollment after commencing in April 2026 — a rapid pace that reflects strong investigator enthusiasm.
-
Study Scope and Timeline
The multicenter trial is expected to enroll patients at up to 30 sites, including international locations, with completion and data readout anticipated in the coming quarters.
-
Upcoming Commentary
Management will provide additional study progress details during the Q2 earnings call on August 6, 2026, offering a near-term catalyst for further updates.
Analysis · PLSE · Industrial Applications And Services
Hitting the halfway point in the NANOPULSE-AF pivotal trial just three months after launch signals strong investigator demand and rapid patient recruitment. This de-risks the timeline for a potential PMA submission and keeps the company on track in the competitive pulsed-field ablation race. With the stock trading near its 52-week high, reflecting elevated expectations, this milestone validates that momentum.
At the time of this filing, PLSE was trading at $35.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $12.56 to $36.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.